Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk (NVO) concluded the recent trading session at $81.05, signifying a +2.95% move from its prior day's close.

Novo Nordisk A/S NVS announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development in weight management. Amycretin is developed for subcutaneous and oral ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Six of the 43 patients without ICBs at baseline (14%) developed transient de novo ICBs after implant; none of them had ICBs at the 3-year observation. Conclusions ICBs were abolished in patients 3 ...

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss ...

A phase 3 trial analysis from FRONTIER5 will evaluate ... thrombin generation with concizumab in hemophilia A/B "At Novo Nordisk, we believe understanding the whole person and their journey ...

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies.